drugset / Trial / NCT02192190

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

NCT02192190

Phase 2 Terminated 268 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.

Timeline

Start
2014-07
Primary completion
2015-04
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg Oral
Subject Galcanezumab Monoclonal antibody 5 mg Subcutaneous
Subject Galcanezumab Monoclonal antibody 50 mg Subcutaneous
Subject Galcanezumab Monoclonal antibody 120 mg Subcutaneous
Subject Galcanezumab Monoclonal antibody 300 mg Subcutaneous

Indications